Velacur: Providing patients with early detection of liver disease

Oct 25, 2022
Sonic Incytes' Velacur logo. A purple to light blue gradient made up of polkadots.

One in five Canadians have nonalcoholic fatty liver disease (NAFLD), which can lead to liver cirrhosis and cancer. While there are no drugs on the market, NAFLD can often be reversed with lifestyle changes, such as diet and exercise. Sadly, given that there are often no initial symptoms, patients tend to go undiagnosed until they arrive in the emergency room presenting with cirrhosis.

Sonic Incytes is helping to diagnose liver disease early, so that patients can take necessary steps to manage this condition.

Based in Vancouver, BC, Sonic Incytes has introduced an innovative tool to the market called Velacur™, which aids in the clinical management of patients with liver disease.

Sonic Incytes’ proprietary technology was invented by University of British Columbia professors Tim Salcudean and Robert Rohling. Velacur™ uses an external activation board similar to MRI elastography to generate steady state shear waves through the liver that are then measured via a typical ultrasound. Based on the relative mechanical properties of the different tissues, liver stiffness and fat can be easily and quickly quantified.

As part of their Pilot Fund project with INOVAIT, Sonic Incytes has been developing AI software to improve the ease of use of Velacur for medical professionals who may not be ultrasound specialists. Sonic Incytes hopes to ultimately achieve adoption in primary care, where liver assessment could, over time, become the next vital sign; similar to the way that blood pressure and heart rate is monitored at a visit to the doctor’s office.

Velacur could be transformational by aiding in the detection of liver disease well before the condition progresses to an advanced stage, giving patients the opportunity to change lifestyle habits before it’s too late.

INOVAIT’s Pilot Fund provides support for commercialization-focused R&D projects involving the integration of AI into image-guided therapy technologies. For more information on how to apply, visit inovait.ca/funding. To learn more about Velacur and Sonic Incytes, visit sonicincytes.com.

Share this on social media

Learn more about the network

INOVAIT launches Canada-wide medtech job board to connect talent with innovation

INOVAIT launches Canada-wide medtech job board to connect talent with innovation

Developed in response to increasing demand from our members and job seekers, the INOVAIT Network Job Board offers job seekers direct access to high-impact roles at some of the country’s top companies working in emerging medical technologies. Updated daily, the platform features listings from across the INOVAIT network and is designed to help talented professionals launch or advance their careers in a home-grown company right here in Canada.

Cohesic flips the script on incorporating AI into healthcare

Cohesic flips the script on incorporating AI into healthcare

Jordan Engbers, Chief Science Officer of Cohesic, a data scientist who spent years in clinical research, is painfully aware of the chasm between the promise and reality of AI in healthcare. While an AI model might work within a study where researchers systematically gather, clean up, and standardize the data, real-world healthcare data is often too messy and unreliable to use for clinical decisions.

Seeing beneath the surface: How MIMOSA is transforming wound care

Seeing beneath the surface: How MIMOSA is transforming wound care

Dr. Karen Cross, a plastic and reconstructive surgeon and CEO of MIMOSA Diagnostics, saw countless patients with diabetes and chronic wounds in her clinic. People with diabetes have an increased risk of developing pressure wounds due to complications like poor circulation and nerve damage. Many of her patients came into her clinic too late to prevent complications and ultimately had lower extremity amputations to prevent fatal infections.